AcuCort

The patent was issued by the INPI (Instituto Nacional da Propriedade Industrial), which is the federal authority responsible for managing the Brazilian system for granting and guaranteeing industrial property rights.

The granted patent means that the oral film is given national protection in Brazil and will expire on November 4, 2035.

"Having this patent granted in Brazil is of great importance for the upcoming market launch of our oral film Zeqmelit®. The approval means that we effectively protect the company's intangible assets," says Jonas Jönmark, CEO of AcuCort.

For further information please contact:

Jonas Jönmark, vd, AcuCort AB

Telefon: 070 365 5400

Epost: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.